Development of the type II cell in the fetal rat lung.

M. C. Williams,R. Mason

DOI: https://doi.org/10.1164/ARRD.1977.115.S.37

1977-06-01

American Review of Respiratory Disease

Abstract:

What problem does this paper attempt to address?

Targeted Neutrophil-Mimetic Liposomes Promote Cardiac Repair by Adsorbing Proinflammatory Cytokines and Regulating the Immune Microenvironment

Chen Jing,Song Yanan,Wang Qiaozi,Li Qiyu,Tan Haipeng,Gao Jinfeng,Zhang Ning,Weng Xueyi,Sun Dili,Yakufu Wusiman,Wang Zhengmin,Qian Juying,Pang Zhiqing,Huang Zheyong,Ge Junbo

DOI: https://doi.org/10.1186/s12951-022-01433-6

IF: 10.2

2022-01-01

Journal of Nanobiotechnology

Abstract:Acute myocardial infarction (MI) induces a sterile inflammatory response that may result in poor cardiac remodeling and dysfunction. Despite the progress in anti-cytokine biologics, anti-inflammation therapy of MI remains unsatisfactory, due largely to the lack of targeting and the complexity of cytokine interactions. Based on the nature of inflammatory chemotaxis and the cytokine-binding properties of neutrophils, we fabricated biomimetic nanoparticles for targeted and broad-spectrum anti-inflammation therapy of MI. By fusing neutrophil membranes with conventional liposomes, we fabricated biomimetic liposomes (Neu-LPs) that inherited the surface antigens of the source cells, making them ideal decoys of neutrophil-targeted biological molecules. Based on their abundant chemokine and cytokine membrane receptors, Neu-LPs targeted infarcted hearts, neutralized proinflammatory cytokines, and thus suppressed intense inflammation and regulated the immune microenvironment. Consequently, Neu-LPs showed significant therapeutic efficacy by providing cardiac protection and promoting angiogenesis in a mouse model of myocardial ischemia-reperfusion. Therefore, Neu-LPs have high clinical translation potential and could be developed as an anti-inflammatory agent to remove broad-spectrum inflammatory cytokines during MI and other neutrophil-involved diseases.
Supramolecular self-assembled nanoparticles camouflaged with neutrophil membrane to mitigate myocardial ischemia/reperfusion (I/R) injury

Xinman Hu,Fang-Yuan Chen,Jie Ding,Zihe Zhai,Huang Yang,Liyin Shen,Yang Zhu,Dong-Sheng Guo,Changyou Gao

DOI: https://doi.org/10.1016/j.cej.2023.148138

IF: 15.1

2023-12-23

Chemical Engineering Journal

Abstract:The clinically restored blood supply post myocardial infarction (MI) will break the physiological and metabolic balance of the ischemic myocardial region, leading to a new injury known as myocardial ischemia/reperfusion (I/R) injury. Abundant oxygen brought by the fresh blood would trigger the damaged myocardium to produce excessive reactive oxygen species (ROS) and thereby inflammation along with the recruitment and infiltration of activated neutrophils and macrophages. Inspired by the active targeting process of inflammatory cells, a novel "neutrophil-like" nanoassembly (At@NQA) was prepared by modifying neutrophil membrane fragments onto At@QA NPs containing 1:1 (molar ratio) calixarene molecule (QA) and anti-inflammatory and anti-fibrotic atorvastatin calcium (At). Tail vein injection of the At@NQA could efficiently target the damaged myocardium, inhibit oxidative damage and inflammation, reduce myocardial fibrosis, increase myocardial troponin T (cTnT) and connexin 43 (Cx43) expression, and thus improve cardiac functions effectively.

engineering, chemical, environmental
3-mercaptolactate cysteine disulfiduria: biochemical studies on affected and unaffected members of a family.

U. Hannestad,J. Mårtensson,R. Sjödahl,B. Sörbo

DOI: https://doi.org/10.1016/0006-2944(81)90035-1

1981-08-01

Biochemical Medicine

Abstract:
Engineered neutrophil apoptotic bodies ameliorate myocardial infarction by promoting macrophage efferocytosis and inflammation resolution

Lili Bao,Geng Dou,Ran Tian,Yajie Lv,Feng Ding,Siying Liu,Ruifeng Zhao,Lu Zhao,Jun Zhou,Lin Weng,Yan Dong,Bei Li,Shiyu Liu,Xin Chen,Yan Jin

DOI: https://doi.org/10.1016/j.bioactmat.2021.08.008

IF: 18.9

2022-03-01

Bioactive Materials

Abstract:Construction of engineered neutrophil apoptotic bodies to simulate natural neutrophil apoptosis.Engineered neutrophil apoptotic bodies with excellent inflammation-tropism and macrophage-specific targeting capacity.Engineered neutrophil apoptotic bodies enhance macrophage efferocytosis and reprogramming for inflammation resolution.Engineered neutrophil apoptotic bodies ameliorate myocardial infarction and promote cardiac tissue regeneration after MI.Inflammatory response plays a critical role in myocardial infarction (MI) repair. The neutrophil apoptosis and subsequent macrophage ingestion can result in inflammation resolution and initiate regeneration, while the therapeutic strategy that simulates and enhances this natural process has not been established. Here, we constructed engineered neutrophil apoptotic bodies (eNABs) to simulate natural neutrophil apoptosis, which regulated inflammation response and enhanced MI repair. The eNABs were fabricated by combining natural neutrophil apoptotic body membrane which has excellent inflammation-tropism and immunoregulatory properties, and mesoporous silica nanoparticles loaded with hexyl 5-aminolevulinate hydrochloride (HAL). The eNABs actively targeted to macrophages and the encapsulated HAL simultaneously initiated the biosynthesis pathway of heme to produce anti-inflammatory bilirubin after intracellular release, thereby further enhancing the anti-inflammation effects. In in vivo studies, the eNABs efficiently modulated inflammation responses in the infarcted region to ameliorate cardiac function. This study demonstrates an effective biomimetic construction strategy to regulate macrophage functions for MI repair.Download : Download high-res image (297KB)Download : Download full-size image

engineering, biomedical,materials science, biomaterials
Enhancing Cardioprotection Through Neutrophil‐Mediated Delivery of 18β‐Glycyrrhetinic Acid in Myocardial Ischemia/Reperfusion Injury

Dongjian Han,Fuhang Wang,Qingjiao Jiang,Zhentao Qiao,Yuansong Zhuang,Quanxu An,Yuhang Li,Yazhe Tang,Chenyao Li,Deliang Shen

DOI: https://doi.org/10.1002/advs.202406124

IF: 15.1

2024-09-14

Advanced Science

Abstract:Innovative neutrophil‐based nanodecoys deliver 18β‐glycyrrhetinic acid directly to damaged heart tissue, simultaneously tackling oxidative stress and inflammation in myocardial ischemia/reperfusion injury (MI/RI). This cutting‐edge approach not only reduces infarct size and enhances cardiac function, but also redefines the landscape of cardioprotection, offering a glimpse into the future of targeted heart therapies. Myocardial ischemia/reperfusion injury (MI/RI) generates reactive oxygen species (ROS) and initiates inflammatory responses. Traditional therapies targeting specific cytokines or ROS often prove inadequate. An innovative drug delivery system (DDS) is developed using neutrophil decoys (NDs) that encapsulate 18β‐glycyrrhetinic acid (GA) within a hydrolyzable oxalate polymer (HOP) and neutrophil membrane vesicles (NMVs). These NDs are responsive to hydrogen peroxide (H2O2), enabling controlled GA release. Additionally, NDs adsorb inflammatory factors, thereby reducing inflammation. They exhibit enhanced adhesion to inflamed endothelial cells (ECs) and improved penetration. Once internalized by cardiomyocytes through clathrin‐mediated endocytosis, NDs protect against ROS‐induced damage and inhibit HMGB1 translocation. In vivo studies show that NDs preferentially accumulate in injured myocardium, reducing infarct size, mitigating adverse remodeling, and enhancing cardiac function, all while maintaining favorable biosafety profiles. This neutrophil‐based system offers a promising targeted therapy for MI/RI by addressing both inflammation and ROS, holding potential for future clinical applications.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Targeted Anti–il-1Β Platelet Microparticles for Cardiac Detoxing and Repair

Zhenhua Li,Shiqi Hu,Ke Huang,Teng Su,Jhon Cores,Ke Cheng

DOI: https://doi.org/10.1126/sciadv.aay0589

IF: 13.6

2020-01-01

Science Advances

Abstract:An acute myocardial infarction (AMI) induces a sterile inflammatory response that facilitates further heart injury and promotes adverse cardiac remodeling. Interleukin-1β (IL-1β) plays a central role in the sterile inflammatory response that results from AMI. Thus, IL-1β blockage is a promising strategy for treatment of AMI. However, conventional IL-1β blockers lack targeting specificity. This increases the risk of serious side effects. To address this problem herein, we fabricated platelet microparticles (PMs) armed with anti-IL-1β antibodies to neutralize IL-1β after AMI and to prevent adverse cardiac remodeling. Our results indicate that the infarct-targeting PMs could bind to the injured heart, increasing the number of anti-IL-1β antibodies therein. The anti-IL-1β platelet PMs (IL1-PMs) protect the cardiomyocytes from apoptosis by neutralizing IL-1β and decreasing IL-1β-driven caspase-3 activity. Our findings indicate that IL1-PM is a promising cardiac detoxification agent that removes cytotoxic IL-1β during AMI and induces therapeutic cardiac repair.
Hippo pathway-manipulating neutrophil-mimic hybrid nanoparticles for cardiac ischemic injury via modulation of local immunity and cardiac regeneration

Qiaozi Wang,Yanan Song,Jinfeng Gao,Qiyu Li,Jing Chen,Yifang Xie,Zhengmin Wang,Haipeng Tan,Hongbo Yang,Ning Zhang,Juying Qian,Zhiqing Pang,Zheyong Huang,Junbo Ge

DOI: https://doi.org/10.1016/j.apsb.2023.08.021

IF: 14.903

2023-08-20

Acta Pharmaceutica Sinica B

Abstract:The promise of regeneration therapy for restoration of damaged myocardium after cardiac ischemic injury relies on targeted delivery of proliferative molecules into cardiomyocytes whose healing benefits are still limited owing to severe immune microenvironment due to local high concentration of proinflammatory cytokines. Optimal therapeutic strategies are therefore in urgent need to both modulate local immunity and deliver proliferative molecules. Here, we addressed this unmet need by developing neutrophil-mimic nanoparticles NM@miR, fabricated by coating hybrid neutrophil membranes with artificial lipids onto mesoporous silica nanoparticles (MSNs) loaded with microRNA-10b. The hybrid membrane could endow nanoparticles with strong capacity to migrate into inflammatory sites and neutralize proinflammatory cytokines and increase the delivery efficiency of microRNA-10b into adult mammalian cardiomyocytes (CMs) by fusing with cell membranes and leading to the release of MSNs-miR into cytosol. Upon NM@miR administration, this nanoparticle could home to the injured myocardium, restore the local immunity, and efficiently deliver microRNA-10b to cardiomyocytes, which could reduce the activation of Hippo-YAP pathway mediated by excessive cytokines and exert the best proliferative effect of miR-10b. This combination therapy could finally improve cardiac function and mitigate ventricular remodeling. Consequently, this work offers a combination strategy of immunity modulation and proliferative molecule delivery to boost cardiac regeneration after injury.

pharmacology & pharmacy
Platelet-Like Fusogenic Liposome-Mediated Targeting Delivery of Mir-21 Improves Myocardial Remodeling by Reprogramming Macrophages Post Myocardial Ischemia-Reperfusion Injury

Haipeng Tan,Ya'nan Song,Jing Chen,Ning Zhang,Qiaozi Wang,Qiyu Li,Jinfeng Gao,Hongbo Yang,Zheng Dong,Xueyi Weng,Zhengmin Wang,Dili Sun,Wusiman Yakufu,Zhiqing Pang,Zheyong Huang,Junbo Ge

DOI: https://doi.org/10.1002/advs.202100787

IF: 15.1

2021-01-01

Advanced Science

Abstract:Inflammatory modulations focusing on macrophage phenotype are promising candidates to promote better cardiac healing post myocardial ischemia-reperfusion (MI/R) injury. However, the peak of monocyte/macrophage recruitment is later than the time when enhanced permeability and retention effect disappears, which greatly increases the difficulty of reprogramming macrophages through systemic administration. Meanwhile, the inability of nanomaterials to release their contents to specific intracellular locations through reasonable cellular internalization pathways is another obstacle to achieving macrophage reprogramming. Here, inspired by the increase in circulating platelet-monocyte aggregates in patients' post-MI/R and the high efficiency of fusogenic liposomes to deliver contents to the cytoplasm of target cells, a platelet-like fusogenic liposome (PLPs) is constructed. Under the coating of PLPs, mesoporous silica nanospheres with a payload of miR-21, an anti-inflammatory agent, can be specifically delivered to inflammatory monocytes in the blood circulation of MI/R induced mice. Then it directly enters the cytoplasm of monocytes through membrane fusion, thereby realizing the reparative reprogramming of the inflamed macrophages derived from it. In vivo administration of the resulting formula can effectively preserve the cardiac function of mice undergone MI/R. Minimal invasiveness and biological safety make this nano-platform a promising approach of immunotherapy.
Biomimetic nanoplatform treats myocardial ischemia/reperfusion injury by synergistically promoting angiogenesis and inhibiting inflammation

Fenting Lei,Jie Zhang,Yiping Deng,Xueqin Wang,Jun Tang,Ji Tian,Ying Wan,Li Wang,Xiangyu Zhou,Yingying Zhang,Chunhong Li

DOI: https://doi.org/10.1016/j.colsurfb.2024.114159

2024-08-10

Abstract:After myocardial ischemia/reperfusion injury (MI/RI), endothelial cell injury causes impaired angiogenesis and obstruction of microcirculation, resulting in an inflammatory outburst that exacerbates the damage. Therefore, synergistic blood vessel repair and inflammation inhibition are effective therapeutic strategies. In this study, we developed a platelet membrane (PM)-encapsulated baicalin nanocrystalline (BA NC) nanoplatform with a high drug load, BA NC@PM, which co-target to endothelial cells and macrophages through the transmembrane proteins of the PM to promote angiogenesis and achieve anti-inflammatory effects. In vitro cell scratch assays and transwell assay manifested that BA NC@PM could promote endothelial cell migration, as well as increase mRNA expression of CD31 and VEGF in the heart after treatment of MI/RI mice, suggesting its favorable vascular repair function. In addition, the preparation significantly reduced the expression of pro-inflammatory factors and increased the expression of anti-inflammatory factors in plasma, promoting the polarization of macrophages. Our study highlights a strategy for enhancing the treatment of MI/RI by promoting angiogenesis and regulating macrophage polarization via the biomimetic BA NC@PM nanoplatform.
Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Jiawen Li,Guidong Gong,Yue Zhang,Yanjiang Zheng,Yunxiang He,Mei Chen,Xianglian He,Xiaolan Zheng,Xue Gong,Lei Liu,Kaiyu Zhou,Zongmin Zhao,C. Wyatt Shields IV,Yimin Hua,Yifei Li,Junling Guo

DOI: https://doi.org/10.1002/adhm.202403595

IF: 10

2024-11-13

Advanced Healthcare Materials

Abstract:This work introduces a cell‐based heart‐specific immunotherapy for myocardial infarction, based on the engineering of a monocyte nanobiohybrid system through polyphenol‐mediated interfacial assembly of interleukin‐10 and microRNA‐19a on the cell surface. This strategy facilitates macrophage immunomodulation toward reparative roles and stimulates cardiac repair, significantly enhancing heart function and offering a novel nanotherapeutic approach for cardiovascular diseases. Myocardial infarction is one of the leading cause of cardiovascular death worldwide. Invasive interventional procedures and medications are applied to attenuate the attacks associated with ischemic heart disease by reestablishing blood flow and restoring oxygen supply. However, the overactivation of inflammatory responses and unsatisfactory drug delivery efficiency in the infarcted regions prohibit functional improvement. Here, a nanoengineered monocyte (MO)‐based biohybrid system, referred to as CTAs @MOs, for the heart‐targeted delivery of combinational therapeutic agents (CTAs) containing anti‐inflammatory IL‐10 and cardiomyogenic miR‐19a to overcome the limitation of malperfusion within the infarcted myocardium through a polyphenol‐mediated interfacial assembly, is reported. Systemic administration of CTAs@MOs bypasses extensive thoracotomy and intramyocardial administration risks, leading to infarcted heart‐specific accumulation and sustained release of therapeutic agents, enabling immunomodulation of the proinflammatory microenvironment and promoting cardiomyocyte proliferation in sequence. Moreover, CTAs@MOs, which serve as a cellular biohybrid‐based therapy, significantly improve cardiac function as evidenced by enhanced ejection fractions, increased fractional shortening, and diminished infarct sizes. This polyphenol nanoengineered biohybrid system represents a general and potent platform for the efficient treatment of cardiovascular disorders.

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction

Han Li,Jing Zhu,Yan-wu Xu,Fang-fang Mou,Xiao-li Shan,Qiang-li Wang,Bao-nian Liu,Ke Ning,Jia-jia Liu,Ya-chao Wang,Jin-xia Mi,Xiaohui Wei,Shui-jin Shao,Guo-hong Cui,Rong Lu,Hai-dong Guo

DOI: https://doi.org/10.1016/j.redox.2022.102384

IF: 11.4

2022-06-25

Redox Biology

Abstract:Notoginsenoside R1 (NGR1) is the main monomeric component extracted from the dried roots and rhizomes of Panax notoginseng, and exerts pharmacological action against myocardial infarction (MI). Owing to the differences in compound distribution, absorption, and metabolism in vivo , exploring a more effective drug delivery system with a high therapeutic targeting effect is crucial. In the early stages of MI, CD11b-expressing monocytes and neutrophils accumulate at infarct sites. Thus, we designed a mesoporous silica nanoparticle-conjugated CD11b antibody with loaded NGR1 (MSN-NGR1-CD11b antibody), which allowed NGR1 precise targeted delivery to the heart in a noninvasively manner. By increasing targeting to the injured myocardium, intravenous injection of MSN-NGR1-CD11b antibody nanoparticle in MI mice improved cardiac function and angiogenesis, reduced cell apoptosis, and regulate macrophage phenotype and inflammatory factors and chemokines. In order to further explore the mechanism of NGR1 protecting myocardium, cell oxidative stress model and oxygen-glucose deprivation (OGD) model were established. NGR1 protected H9C2 cells and primary cardiomyocytes against oxidative injury induced by H 2 O 2 and OGD treatment. Further network pharmacology and molecular docking analyses suggested that the AKT, MAPK and Hippo signaling pathways were involved in the regulation of NGR1 in myocardial protection. Indeed, NGR1 could elevate the levels of p-Akt and p-ERK, and promote the nuclear translocation of YAP. Furthermore, LY294002 (AKT inhibitor), U0126 (ERK1/2 inhibitor) and Verteporfin (YAP inhibitor) administration in H9C2 cells indicated the involvement of AKT, MAPK and Hippo signaling pathways in NGR1 effects. Meanwhile, MSN-NGR1-CD11b antibody nanoparticles enhanced the activation of AKT and MAPK signaling pathways and the nuclear translocation of YAP at the infarcted site. Our research demonstrated that MSN-NGR1-CD11b antibody nanoparticle injection after MI enhanced the targeting of NGR1 to the infarcted myocardium and improved cardiac function. More importantly, our pioneering research provides a new strategy for targeting drug delivery systems to the ischemic niche.

biochemistry & molecular biology
Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment

Chunping Liu,Zhijin Fan,Dongyue He,Huiqi Chen,Shihui Zhang,Sien Guo,Bojun Zheng,Huan Cen,Yunxuan Zhao,Hongxing Liu,Lei Wang

DOI: https://doi.org/10.3390/pharmaceutics14040758

IF: 6.525

2022-03-31

Pharmaceutics

Abstract:Acute myocardial infarction is a major global health problem, and the repair of damaged myocardium is still a major challenge. Myocardial injury triggers an inflammatory response: immune cells infiltrate into the myocardium while activating myofibroblasts and vascular endothelial cells, promoting tissue repair and scar formation. Fragments released by cardiomyocytes become endogenous “danger signals”, which are recognized by cardiac pattern recognition receptors, activate resident cardiac immune cells, release thrombin factors and inflammatory mediators, and trigger severe inflammatory responses. Inflammatory signaling plays an important role in the dilation and fibrosis remodeling of the infarcted heart, and is a key event driving the pathogenesis of post-infarct heart failure. At present, there is no effective way to reverse the inflammatory microenvironment in injured myocardium, so it is urgent to find new therapeutic and diagnostic strategies. Nanomedicine, the application of nanoparticles for the prevention, treatment, and imaging of disease, has produced a number of promising applications. This review discusses the treatment and challenges of myocardial injury and describes the advantages of functional nanoparticles in regulating the myocardial inflammatory microenvironment and overcoming side effects. In addition, the role of inflammatory signals in regulating the repair and remodeling of infarcted hearts is discussed, and specific therapeutic targets are identified to provide new therapeutic ideas for the treatment of myocardial injury.

pharmacology & pharmacy
Targeted Delivery of Apoptotic Cell‐Derived Nanovesicles prevents Cardiac Remodeling and Attenuates Cardiac Function Exacerbation

Ju‐Ro Lee,Woo‐Sup Sim,Hun‐Jun Park,Bong‐Woo Park,Yoon Ki Joung

DOI: https://doi.org/10.1002/adfm.202210864

IF: 19

2023-01-29

Advanced Functional Materials

Abstract:Dextran‐ and ischemic cardiac homing peptide‐conjugated apoptotic cell‐derived nanovesicles (ApoNV‐DCs) actively target infarcted myocardium and are selectively phagocytosed by macrophages in infarcted heart. ApoNV‐DCs polarize macrophages M1 to M2 phenotype and decrease inflammatory responses. Immunomodulation by ApoNV‐DCs not only reduce cardiac adverse remodeling but also prevent cardiac function aggravation after myocardial ischemia‐reperfusion injury. The modulation of inflammatory responses plays an important role in the pathobiology of cardiac failure. In a natural healing process, the ingestion of apoptotic cells and their apoptotic bodies by macrophages in a focal lesion result in resolution of inflammation and regeneration. However, therapeutic strategies to enhance this natural healing process using apoptotic cell‐derived biomaterials have not yet been established. In this study, apoptotic bodies‐mimetic nanovesicles derived from apoptotic fibroblasts (ApoNVs) conjugated with dextran and ischemic cardiac homing peptide (CHP) (ApoNV‐DCs) for ischemia‐reperfusion (IR)‐injured heart treatment are developed. Intravenously injected ApoNV‐DCs actively targeted the ischemic myocardium via conjugation with CHP, and are selectively phagocytosed by macrophages in an infarcted myocardium via conjugation with dextran. ApoNV‐DCs polarized macrophages from the M1 to M2 phenotype, resulting in the attenuation of inflammation. Four weeks after injection, ApoNV‐DCs attenuated cardiac remodeling, preserved blood vessels, and prevented cardiac function exacerbation in IR‐injured hearts. Taken together, the findings may open a new avenue for immunomodulation using targeted delivery of anti‐inflammatory nanovesicles that can be universally applied for various inflammatory diseases.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction

Jun Yan Xu,Yu Yan Xiong,Rui Jie Tang,Wen Yang Jiang,Yu Ning,Zhao Ting Gong,Pei Sen Huang,Gui Hao Chen,Jun Xu,Chun Xiao Wu,Meng Jin Hu,Jing Xu,Yi Xu,Cun Rong Huang,Chen Jin,Xiao Tong Lu,Hai Yan Qian,Xiang Dong Li,Yue Jin Yang,Jun-Yan Xu,Yu-Yan Xiong,Rui-Jie Tang,Wen-Yang Jiang,Zhao-Ting Gong,Pei-Sen Huang,Gui-Hao Chen,Chun-Xiao Wu,Meng-Jin Hu,Cun-Rong Huang,Xiao-Tong Lu,Hai-Yan Qian,Xiang-Dong Li,Yue-Jin Yang

DOI: https://doi.org/10.1093/cvr/cvab237

IF: 13.081

2021-07-14

Cardiovascular Research

Abstract:Abstract Aims Interleukin (IL)-5 mediates the development of eosinophils (EOS) that are essential for tissue post-injury repair. It remains unknown whether IL-5 plays a role in heart repair after myocardial infarction (MI). This study aims to test whether IL-5-induced EOS population promotes the healing and repair process post-MI and to reveal the underlying mechanisms. Methods and results MI was induced by permanent ligation of the left anterior descending coronary artery in wild-type C57BL/6 mice. Western blot and real-time polymerase chain reaction revealed elevated expression of IL-5 in the heart at 5 days post-MI. Immunohistostaining indicated that IL-5 was secreted mainly from macrophages and CD127+ cells in the setting of experimental MI. External supply of recombinant mouse IL-5 (20 min, 1 day, and 2 days after MI surgery) reduced the infarct size and increased ejection fraction and angiogenesis in the border zone. A significant expansion of EOS was detected in both the peripheral blood and infarcted myocardium after IL-5 administration. Pharmacological depletion of EOS by TRFK5 pretreatment muted the beneficial effects of IL-5 in MI mice. Mechanistic studies demonstrated that IL-5 increased the accumulation of CD206+ macrophages in infarcted myocardium at 7 days post-MI. In vitro co-culture experiments showed that EOS shifted bone marrow-derived macrophage polarization towards the CD206+ phenotypes. This activity of EOS was abolished by IL-4 neutralizing antibody, but not IL-10 or IL-13 neutralization. Western blot analyses demonstrated that EOS promoted the macrophage downstream signal transducer and activator of transcription 6 (STAT6) phosphorylation. Conclusion IL-5 facilitates the recovery of cardiac dysfunction post-MI by promoting EOS accumulation and subsequent CD206+ macrophage polarization via the IL-4/STAT6 axis.

cardiac & cardiovascular systems
Targeting Cardiac Resident CCR2+ Macrophage-Secreted MCP-1 to Attenuate Inflammation After Myocardial Infarction

Jiaxing Wen,Ya Guan,Hong Niu,Yu Dang,Jianjun Guan

DOI: https://doi.org/10.1016/j.actbio.2024.08.025

2024-08-23

Abstract:After myocardial infarction (MI), cardiac resident CCR2+ macrophages release various cytokines and chemokines, notably monocyte chemoattractant protein-1 (MCP-1). MCP-1 is instrumental in recruiting CCR2+ monocytes to the damaged region. The excessive arrival of these monocytes, which then become macrophages, perpetuates inflammation at the site of injury. This continuous inflammation leads to adverse tissue remodeling and compromises cardiac function over time. We hypothesized that neutralizing the MCP-1 secreted by cardiac resident CCR2+ macrophages can mitigate post-MI inflammation by curtailing the recruitment of monocytes and their differentiation into macrophages. In this work, we developed nanoparticles that target the infarcted heart, specifically accumulating in the damaged area after intravenous (IV) administration, and docking onto CCR2+ macrophages. These nanoparticles were designed to slowly release an MCP-1 binding peptide, HSWRHFHTLGGG (HSW), which neutralizes the upregulated MCP-1. We showed that the HSW reduced monocyte migration, inhibited pro-inflammatory cytokine upregulation, and suppressed myofibroblast differentiation in vitro. After IV delivery, the released HSW significantly decreased monocyte recruitment and pro-inflammatory macrophage density, increased cardiac cell survival, attenuated cardiac fibrosis, and improved cardiac function. Taken together, our findings support the strategy of MCP-1 neutralization at the acute phase of MI as a promising way to alleviate post-MI inflammation. STATEMENT OF SIGNIFICANCE: After a myocardial infarction (MI), CCR2+ macrophages resident in the heart release various cytokines and chemokines, notably monocyte chemoattractant protein-1 (MCP-1). MCP-1 is instrumental in attracting CCR2+ monocytes to the damaged region. The excessive arrival of these monocytes, which then become macrophages, perpetuates inflammation at the site of injury. This continuous inflammation leads to adverse tissue remodeling and compromises cardiac function over time. In this work, we tested the hypothesis that neutralizing the MCP-1 secreted by cardiac CCR2+ macrophages can mitigate post-MI inflammation by curtailing the recruitment of monocytes.
Promoting Cardiac Repair Through Simple Engineering of Nanoparticles with Exclusive Targeting Capability Toward Myocardial Reperfusion Injury by Thermal Resistant Microfluidic Platform

Zehua Liu,Wenhua Lian,Qiang Long,Ruoyu Cheng,Giulia Torrieri,Baoding Zhang,Artturi Koivuniemi,Mohammad Mahmoudzadeh,Alex Bunker,Han Gao,Hongbin He,Yun Chen,Jouni Hirvonen,Rongbin Zhou,Qiang Zhao,Xiaofeng Ye,Xianming Deng,Helder A. Santos

DOI: https://doi.org/10.1002/adfm.202204666

IF: 19

2022-01-01

Advanced Functional Materials

Abstract:Nanoparticle (NP)‐based intravenous administration represents the most convenient cardiac targeting delivery routine, yet, there are still therapeutic issues due to the lack of targeting efficiency and specificity. Active targeting methods using functionalization of ligands onto the NPs’ surface may be limited by trivial modification procedures and reduced targeting yield in vivo. Here, a microfluidics assisted single step, green synthesis method is introduced for producing targeting ligands free heart homing NPs in a tailored manner. The generated β‐glucan‐based NPs exhibit precise and efficient targeting capability toward Dectin‐1 + monocytes/macrophages, which are confirmed as main pathogenesis mediators for cardiac ischemic/reperfusion (I/R) injury, with a sequentially enhanced cardiac NP accumulation, and this targeting strategy is exclusively suitable for cardiac I/R but not for other cardiovascular diseases, as confirmed both in murine and human model. Comparing to FDA‐approved nano‐micelles formulation, β‐glucan NPs loaded with NACHT, LRR, and PYD domains‐containing protein 3 (NLRP3) inflammasome inhibitor (CY‐09) exhibit better efficiency in ameliorating myocardial injury and heart failure induced by surgically induced I/R. These findings indicate a simple production of targeting‐ligand free NPs, and demonstrate their potential therapeutic applications for preclinical I/R‐induced cardiac injury amelioration.
Neutrophil-mediated cardiac damage after acute myocardial infarction: Significance of defining a new target cell-type for developing cardioprotective drugs.

P. Witting,Shane R Thomas,J. Dennis,M. El Kazzi,B. Chami,B. Rayner

DOI: https://doi.org/10.1089/ars.2019.7928

2020-06-10

Antioxidants and Redox Signaling

Abstract:SIGNIFICANCE Acute myocardial infarction (AMI) is a leading cause of death worldwide. Post-AMI survival rates have increased with the introduction of angioplasty as a primary coronary intervention. However, reperfusion after angioplasty represents a clinical paradox, restoring blood flow to the ischemic myocardium while simultaneously inducing ion and metabolic imbalances that stimulate immune cell recruitement and activation, mitochondrial dysfunction and damaging oxidant production. Recent Advances: Preclinical data indicate that these metabolic imbalances contribute to subsequent heart failure through sustaining local recruitment of inflammatory leukocytes and oxidative stress, cardiomyocyte death and coronary microvascular disturbances, which enhance adverse cardiac remodelling. Both left ventricular dysfunction and heart failure are strongly linked to inflammation and immune cell recruitment to the damaged myocardium. CRITICAL ISSUES Therapeutic anti-inflammatory and antioxidant agents identified in preclinical trials have overall failed in clinical trials. FUTURE DIRECTIONS The versatile neutrophil-derived heme enzyme, myeloperoxidase, is gaining attention as an important oxidative mediator of reperfusion injury, vascular dysfunction, adverse ventricular remodelling and atrial fibrillation. Accordingly, there is interest in therapeutically targeting neutrophils and myeloperoxidase activity in the setting of heart failure. Herein we discuss the role of post-AMI inflammation linked to myocardial damage and heart failure, describe previous trials targeting inflammation and oxidative stress post-AMI, highlight the potential adverse impact of neutrophil and myeloperoxidase, and detail therapeutic options available to target myeloperoxidase clinically in AMI patients.

Medicine
Abstract 18536: Nanoparticle-mediated Simultaneous Targeting to Mitochondria and Inflammatory Monocytes Confers Additive Cardioprotection Against Myocardial Ischemia-reperfusion Injury

Gentaro Ikeda,Tetsuya Matoba,Kensuke Egashira

DOI: https://doi.org/10.1161/circ.132.suppl_3.18536

IF: 37.8

2015-11-10

Circulation

Abstract:Introduction: Mitochondrial injury and inflammation play temporally and spatially different roles in myocardial ischemia-reperfusion (IR) injury, which demand novel strategy to target these 2 mediators specifically. Previously, we have engineered poly (lactic-co-glycolic acid) nanoparticle containing cyclosporine A (CsA-NP) or pitavastatin (Pit-NP), and reported that the former inhibits the opening of mitochondrial permeability transition pore (mPTP) and the latter reduces monocyte-mediated inflammation in IR hearts. Hypothesis: Nanoparticle-mediated simultaneous targeting to mPTP and monocytes confer additive cardioprotection against IR injury. Methods and Results: We produced mice lacking both cyclophilin D (CypD, a key molecule for mPTP opening) and CCR2 (a receptor for monocyte chemoattractant protein-1), and found that the double KO mice displayed dramatic reduction in myocardial IR injury model (Fig. A). Fluorescence reflectance image (FRI) revealed that CypD deficiency reduced Annexin-positive infarct area in the center of ischemic area, compared with WT mice at 10 min after reperfusion (Fig. B). Although infarct areas were equivalent between WT and CCR2 KO mice at 10 min after reperfusion, CCR2 deficiency inhibited the expansion of the infarct area during 24 hours. Flow cytometric analysis and fluorescence molecular tomography showed that inflammation was markedly inhibited in CCR2 KO and double KO mice, but not in CypD KO mice at 24 hours after reperfusion (Fig. C). In CypD KO mice, Pit-NP reduced recruitment of Ly6Chigh inflammatory monocytes and infarct size, whereas CsA-NP reduced infarct size in CCR2 KO mice. Simultaneous treatment with CsA-NP and Pit-NP at the time of reperfusion reduced infarct size by an additive manner (Fig. D). Conclusions: Nanoparticle-mediated simultaneous targeting to mitochondria and inflammatory monocytes can be developed as a novel therapeutic strategy for myocardial IR injury.

cardiac & cardiovascular systems,peripheral vascular disease
Inflammation‐Targeted Nanomedicines Alleviate Oxidative Stress and Reprogram Macrophages Polarization for Myocardial Infarction Treatment

Danrong Hu,Ran Li,Yicong Li,Meng Wang,Lu Wang,Shiqi Wang,Hongxin Cheng,Qing Zhang,Chenying Fu,Zhiyong Qian,Quan Wei

DOI: https://doi.org/10.1002/advs.202308910

IF: 15.1

2024-04-08

Advanced Science

Abstract:In article number 202308910, Danrong Hu, Ran Li, and co‐workers report the design, preparation, and evaluation of a newly constructed mannan‐based nanomedicine, Que@MOF/Man, which achieved inflammation‐targeting delivery of the antioxidative and anti‐inflammatory agent quercetin (Que) to the infarcted heart. Myocardial infarction (MI) is a critical global health challenge, with current treatments limited by the complex MI microenvironment, particularly the excessive oxidative stress and intense inflammatory responses that exacerbate cardiac dysfunction and MI progression. Herein, a mannan‐based nanomedicine, Que@MOF/Man, is developed to target the inflammatory infarcted heart and deliver the antioxidative and anti‐inflammatory agent quercetin (Que), thereby facilitating a beneficial myocardial microenvironment for cardiac repair. The presence of mannan on the nanoparticle surface enables selective internalization by macrophages rather than cardiomyocytes. Que@MOF/Man effectively neutralizes reactive oxygen species in macrophages to reduce oxidative stress and promote their differentiation into a reparative phenotype, reconciling the inflammatory response and enhancing cardiomyocyte survival through intercellular communication. Owing to the recruitment of macrophages into inflamed myocardium post‐MI, in vivo, administration of Que@MOF/Man in MI rats revealed the specific distribution into the injured myocardium compared to free Que. Furthermore, Que@MOF/Man exhibited favorable results in resolving inflammation and protecting cardiomyocytes, thereby preventing further myocardial remodeling and improving cardiac function in MI rats. These findings collectively validate the rational design of an inflammation‐targeted delivery strategy to mitigate oxidative stress and modulate the inflammation response in the injured heart, presenting a therapeutic avenue for MI treatment.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
An Injectable Hydrogel Containing Versatile Nanoparticles with Antioxidant and Antifibrotic Properties for Myocardial Infarction Treatment

Hong Yang,Jingjing Li,Han Shen,Dongxu Jia,Yujuan Jia,Zhu Wang,Qian Yu,Zhenya Shen,Yanxia Zhang

DOI: https://doi.org/10.1016/j.jmst.2024.07.028

2025-01-01

Journal of Material Science and Technology

Abstract:Myocardial infarction (MI) continues to be the primary cause of death globally. Oxidative stress in the initial phase of MI, followed by uncontrolled and excessive myocardial fibrosis, significantly impedes cardiac repair efficiency post-MI, culminating in adverse ventricular remodeling and potential heart failure. To address the diverse pathological stages of MI, an injectable composite hydrogel containing versatile nanoparticles was developed. In this study, mesoporous silicon nanoparticles (MSNs) served as carriers for encapsulating microRNA-29b (miR-29b) mimics with antifibrotic activity, subsequently coated with a complex of natural antioxidant tannic acid and zinc ions (TA/Zn). These nanoparticles were then embedded into a biocompatible alginate hydrogel to enhance retention within the infarcted myocardium. Upon injection into the infarcted region of MI mice, the composite hydrogel gradually released the nanoparticles as it degraded. Initially, the TA/Zn complex on the outer layer scavenged reactive oxygen species, thereby inhibiting cell apoptosis. The subsequent dissociation of the TA/Zn complex led to the release of the encapsulated miR-29b mimics that could inhibit the activation of cardiac fibroblasts and collagen production, thereby alleviating fibrosis progression. Overall, this composite hydrogel demonstrated the potential to reduce infarct size and improve cardiac function, suggesting its promise as a synergistic therapeutic approach for repairing infarcted myocardium. (c) 2024 Published by Elsevier Ltd on behalf of The editorial office of Journal of Materials Science & Technology.

Development of the type II cell in the fetal rat lung.

Targeted Neutrophil-Mimetic Liposomes Promote Cardiac Repair by Adsorbing Proinflammatory Cytokines and Regulating the Immune Microenvironment

Supramolecular self-assembled nanoparticles camouflaged with neutrophil membrane to mitigate myocardial ischemia/reperfusion (I/R) injury

3-mercaptolactate cysteine disulfiduria: biochemical studies on affected and unaffected members of a family.

Engineered neutrophil apoptotic bodies ameliorate myocardial infarction by promoting macrophage efferocytosis and inflammation resolution

Enhancing Cardioprotection Through Neutrophil‐Mediated Delivery of 18β‐Glycyrrhetinic Acid in Myocardial Ischemia/Reperfusion Injury

Targeted Anti–il-1Β Platelet Microparticles for Cardiac Detoxing and Repair

Hippo pathway-manipulating neutrophil-mimic hybrid nanoparticles for cardiac ischemic injury via modulation of local immunity and cardiac regeneration

Platelet-Like Fusogenic Liposome-Mediated Targeting Delivery of Mir-21 Improves Myocardial Remodeling by Reprogramming Macrophages Post Myocardial Ischemia-Reperfusion Injury

Biomimetic nanoplatform treats myocardial ischemia/reperfusion injury by synergistically promoting angiogenesis and inhibiting inflammation

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction

Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment

Targeted Delivery of Apoptotic Cell‐Derived Nanovesicles prevents Cardiac Remodeling and Attenuates Cardiac Function Exacerbation

Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction

Targeting Cardiac Resident CCR2+ Macrophage-Secreted MCP-1 to Attenuate Inflammation After Myocardial Infarction

Promoting Cardiac Repair Through Simple Engineering of Nanoparticles with Exclusive Targeting Capability Toward Myocardial Reperfusion Injury by Thermal Resistant Microfluidic Platform

Neutrophil-mediated cardiac damage after acute myocardial infarction: Significance of defining a new target cell-type for developing cardioprotective drugs.

Abstract 18536: Nanoparticle-mediated Simultaneous Targeting to Mitochondria and Inflammatory Monocytes Confers Additive Cardioprotection Against Myocardial Ischemia-reperfusion Injury

Inflammation‐Targeted Nanomedicines Alleviate Oxidative Stress and Reprogram Macrophages Polarization for Myocardial Infarction Treatment

An Injectable Hydrogel Containing Versatile Nanoparticles with Antioxidant and Antifibrotic Properties for Myocardial Infarction Treatment